RESUMO
Palmoplantar pustulosis is a variant of psoriasis and a chronic skin disorder in which pruritic pustular eruptions appear on the palms and soles. It is thought to arise from a variety of genetic and environmental factors, is limited in prevalence, and has proven quite difficult to treat. The symptoms it inflicts on those affected are quite debilitating and the treatment landscape is constantly evolving, thus emphasizing the need for updates of the literature as time passes. Current treatments include topical agents, oral therapies, and phototherapy, amongst other treatments. In this systemic review, we explore newer literature from 2015 to 2022 on various treatment regimens for palmoplantar pustulosis. J Drugs Dermatol. 2024;23(8):626-631. doi:10.36849/JDD.doi:10.36849/7612R1.
Assuntos
Fármacos Dermatológicos , Psoríase , Humanos , Psoríase/terapia , Psoríase/diagnóstico , Psoríase/tratamento farmacológico , Fármacos Dermatológicos/uso terapêutico , Fármacos Dermatológicos/administração & dosagem , Fototerapia/métodos , Administração Oral , Administração Cutânea , Resultado do TratamentoAssuntos
Alopecia , Humanos , Feminino , LDL-Colesterol , Alopecia/diagnóstico , Alopecia/complicaçõesAssuntos
Inibidores de Calcineurina , Couro Cabeludo , Humanos , Inibidores de Calcineurina/efeitos adversos , Couro Cabeludo/patologia , Cicatriz/induzido quimicamente , Cicatriz/patologia , Alopecia/induzido quimicamente , Alopecia/tratamento farmacológico , Alopecia/patologia , Atrofia/induzido quimicamente , Atrofia/patologia , EsteroidesRESUMO
Background: Alopecia areata (AA) is a chronic autoimmune disease that causes non-scarring alopecia. A few studies have shown increased odds of AA in Black individuals compared to White individuals and increased odds of AA in Latinos compared to non-Latinos. Another study showed that Asians have lower odds of AA compared to Whites. Baricitinib, a Janus kinase inhibitor (JAKi), became the first Federal Drug Administration (FDA)-approved medication for adult patients with severe AA in June 2022. Objectives: The aim of this review was to analyze published JAKi AA randomized controlled trials to characterize and assess the racial and ethnic representation of participants. Animal studies, studies unrelated to AA, and studies not investigating JAKis were excluded. Methods: PubMed and clinicaltrials.gov were searched for systematic reviews of clinical trials between 1990 and 2022. Results: Six clinical trials were included with a total of 1,690 subjects. Four trials were industry-sponsored, while two were university-sponsored. The three largest races represented included White (59.9%), Asian (28.0%), and African American/Black (8.1%). Three out of the 10 patients identified as Hispanic. None of the trials included sub-analyses of clinical efficacy based on race and/or ethnicity. Conclusions: Our results show that populations with lower odds of AA (Whites and Asians) are overrepresented in JAKi AA clinical trials compared to Black and Hispanic/Latino patients.
Assuntos
Psoríase , Humanos , Adulto , Fatores Socioeconômicos , Inquéritos Epidemiológicos , Psoríase/epidemiologiaAssuntos
Obesidade , Psoríase , Adulto , Humanos , Inquéritos Nutricionais , Obesidade/complicações , Obesidade/epidemiologia , Psoríase/epidemiologiaRESUMO
Primary cicatricial alopecia can result in permanent hair loss from the destruction of hair follicles. Early intervention is key in controlling disease progression, reducing symptoms, and optimizing hair density. Treatment modalities range from topical and intralesional therapies to oral medications and light therapy.
Assuntos
Alopecia , Cicatriz , Humanos , Cicatriz/etiologia , Cicatriz/terapia , Alopecia/terapia , Cabelo , Intervenção Educacional Precoce , FototerapiaRESUMO
Atopic dermatitis (AD) is a common, chronic inflammatory dermatologic condition that can cause discomfort and thus negatively influence the mental health of patients. Research directly exploring the relationship between AD, anxiety, and symptoms of panic in a large United States (US) adult population is limited. We studied the relationship between AD and anxiety versus panic in US adults aged 20 to 39 years. The association between AD and anxiety was significant, but not between AD and panic. This association between AD and anxiety was significantly increased in adults aged 30 to 39 years and female adults. Our study may demonstrate that a focus on the wellbeing of patients might be helpful in clinical practice. Further longitudinal studies can help to elucidate these relationships.